AI filing briefs · archive

8-K filings in July 2024, explained

392 material Form 8-K filings that 341 companies we cover made with the SEC in July 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).

2 of 392 briefs match

newest first · times in ET

CHDNChurchill Downs Inc Jul 3, 4:16 PM ET

Churchill Downs extends revolver and Term Loan A maturities from 2027 to 2029

Neutral financing Written later 1.01

Churchill Downs closed an amendment to its senior secured credit agreement that extends the maturity of its revolving credit facility and Term Loan A from 2027 to 2029, and makes other changes to the agreement. The filing does not disclose borrowing amounts or pricing changes beyond the existing SOFR-based structure, so the effect is a longer repayment runway for the company's bank debt.

Revolver and Term Loan A maturities extended from 2027 to July 3, 2029
Sixth Amendment includes a springing maturity if other material debt maturing before July 3, 2029 is not refinanced at least 91 days before its stated maturity
Loans continue to bear interest at SOFR plus a margin based on leverage ratio; JPMorgan Chase Bank, N.A. is administrative agent

Read the filing on SEC.gov ↗

DGXQUEST DIAGNOSTICS INC Jul 3, 9:18 AM ET

Quest Diagnostics agrees to buy Canada's LifeLabs from OMERS for $985 million

Neutral m&a Written later 1.01 7.01

Quest Diagnostics signed an agreement on July 2, 2024 to acquire LifeLabs, a Canadian provider of laboratory diagnostic services, from OMERS for about 1.35 billion Canadian dollars (about $985 million U.S.), including net debt. The company expects to fund the deal with cash on hand and debt, and expects it to close by the end of 2024, subject to customer consents and Canadian regulatory approvals.

Purchase price is about CAN $1.35 billion (about USD $985 million), including net debt, subject to customary adjustments.
The company expects the deal to add about CAN $970 million (about USD $710 million) in annual revenue.
Quest expects the deal to be slightly dilutive to GAAP EPS but accretive to adjusted EPS in the first 12 months after closing.
Closing is expected by the end of the year and depends on customer consents and Competition Act and Investment Canada Act conditions.

Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.